Haloxon

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Haloxon
Accession Number
DB11419
Type
Small Molecule
Groups
Vet approved
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
T8KXA37068
CAS number
Not Available
Weight
Average: 415.58
Monoisotopic: 413.9593583
Chemical Formula
C14H14Cl3O6P
InChI Key
KULDXINYXFTXMO-UHFFFAOYSA-N
InChI
InChI=1S/C14H14Cl3O6P/c1-9-11-3-2-10(8-12(11)22-14(18)13(9)17)23-24(19,20-6-4-15)21-7-5-16/h2-3,8H,4-7H2,1H3
IUPAC Name
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl bis(2-chloroethyl) phosphate
SMILES
CC1=C(Cl)C(=O)OC2=C1C=CC(OP(=O)(OCCCl)OCCCl)=C2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
DexmethylphenidateThe serum concentration of the active metabolites of Haloxon can be increased when Haloxon is used in combination with Dexmethylphenidate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Humphreys DJ, Stodulski JB, Fysh RR, Howie NM: Haloxon poisoning in geese. Vet Rec. 1980 Dec 6;107(23):541. [PubMed:7467105]
  2. Cook TF: Toxicity of haloxon in sheep. N Z Vet J. 1966 May-Jun;14(5-6):71-2. [PubMed:5222053]
  3. Benz GW: Anthelmintic activity of haloxon in calves. Am J Vet Res. 1972 Jun;33(6):1273-6. [PubMed:5022406]
  4. Cook TF: The anthelmintic efficiency of haloxon in horses. N Z Vet J. 1973 May;21(5):82-4. [PubMed:4517371]
  5. BAKER NF, DOUGLAS JR: ANTHELMINTIC ACTIVITY OF HALOXON IN LAMBS. Am J Vet Res. 1965 May;26:651-3. [PubMed:14316778]
  6. Beech JA: Field trials with haloxon against Capillaria in laying fowls. Vet Rec. 1967 Feb 4;80(5):195-8. [PubMed:6067853]
  7. Lyons ET, Drudge JH, Tolliver SC: Haloxon: critical tests of antiparasitic activity in equids. Am J Vet Res. 1981 Jun;42(6):1043-5. [PubMed:7283234]
  8. Kingsbury PA, Rees TA, Piercy DW: Haloxon as an anthelmintic for dogs and cats. Vet Rec. 1977 Dec 10;101(24):477-9. [PubMed:272801]
  9. Rose RJ, Hartley WJ, Baker W: Laryngeal paralysis in Arabian foals associated with oral haloxon administration. Equine Vet J. 1981 Jul;13(3):171-6. [PubMed:7297547]
  10. Baker NF, Douglas JR, Fisk RA: Anthelmintic activity of haloxon in calves with parasitic gastroenteritis. Am J Vet Res. 1969 Dec;30(12):2233-5. [PubMed:5389428]
External Links
ChemSpider
9082
ChEMBL
CHEMBL1897362
Wikipedia
Haloxon

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0206 mg/mLALOGPS
logP3.4ALOGPS
logP3.87ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)-7.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area71.06 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity91.13 m3·mol-1ChemAxon
Polarizability37.1 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Not Available
Direct Parent
Coumarins and derivatives
Alternative Parents
1-benzopyrans / Pyranones and derivatives / Dialkyl phosphates / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organochlorides
show 3 more
Substituents
Coumarin / Benzopyran / 1-benzopyran / Pyranone / Dialkyl phosphate / Aryl chloride / Aryl halide / Organic phosphoric acid derivative / Phosphoric acid ester / Pyran
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on February 25, 2016 11:37 / Updated on June 04, 2019 07:21